Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$108.01 - $179.35 $247,990 - $411,787
2,296 New
2,296 $408,000
Q2 2023

Aug 10, 2023

BUY
$78.48 - $130.32 $5,179 - $8,601
66 Added 0.94%
7,056 $828,000
Q1 2023

May 09, 2023

SELL
$72.39 - $84.27 $695,016 - $809,076
-9,601 Reduced 57.87%
6,990 $559,000
Q4 2022

Feb 10, 2023

SELL
$63.14 - $79.9 $498,111 - $630,331
-7,889 Reduced 32.23%
16,591 $1.31 Million
Q3 2022

Nov 10, 2022

BUY
$64.85 - $82.4 $1.38 Million - $1.75 Million
21,278 Added 664.52%
24,480 $1.71 Million
Q2 2022

Aug 05, 2022

BUY
$48.93 - $73.47 $156,673 - $235,250
3,202 New
3,202 $210,000
Q1 2022

May 12, 2022

SELL
$51.99 - $72.11 $591,178 - $819,962
-11,371 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$39.81 - $88.24 $452,679 - $1 Million
11,371 New
11,371 $795,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.